Logo

RPID

Rapid Micro Biosystems, Inc.

RPID

Rapid Micro Biosystems, Inc. • NASDAQ
$4.19 ▲ 1.21% (+0.05)
Market Cap $185.79 M
52w High $4.50
52w Low $0.87
Dividend Yield 0%
P/E -4.19
Volume 40.32K
Outstanding Shares 44.34M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $7.838M ▲ $13.647M ▼ $-11.505M ▲ -146.785% ▲ $-0.25 ▲ $-10.276M ▲
Q2-2025 $7.262M ▲ $14.095M ▲ $-11.858M ▼ -163.288% ▼ $-0.27 ▼ $-11.036M ▼
Q1-2025 $7.205M ▼ $12.065M ▲ $-11.263M ▼ -156.322% ▼ $-0.26 ▼ $-10.814M ▼
Q4-2024 $8.218M ▲ $11.21M ▼ $-9.666M ▲ -117.62% ▲ $-0.22 ▲ $-9.36M ▲
Q3-2024 $7.604M $12.661M $-11.323M -148.908% $-0.26 $-11.31M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $41.248M ▲ $84.407M ▲ $40.075M ▲ $44.332M ▼
Q2-2025 $31.255M ▼ $75.586M ▼ $21.041M ▲ $54.545M ▼
Q1-2025 $41.67M ▼ $85.434M ▼ $19.943M ▼ $65.491M ▼
Q4-2024 $50.732M ▼ $98.169M ▼ $22.817M ▲ $75.352M ▼
Q3-2024 $60.832M $105.843M $21.47M $84.373M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-11.505M ▲ $-9.051M ▲ $-9.583M ▼ $19.247M ▲ $613K ▲ $-9.124M ▲
Q2-2025 $-11.858M ▼ $-9.7M ▼ $9.344M ▼ $-298K ▼ $-573K ▼ $-10.066M ▼
Q1-2025 $-11.263M ▼ $-9.065M ▲ $10.681M ▲ $379K ▲ $1.995M ▲ $-9.384M ▲
Q4-2024 $-9.666M ▲ $-9.909M ▼ $4.863M ▲ $-6K ▼ $-5.052M ▲ $-10.007M ▼
Q3-2024 $-11.323M $-8.6M $-6.538M $61K $-15.077M $-8.823M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Product
Product
 $10.00M ▲$10.00M ▲$10.00M ▲$10.00M ▲
Service
Service
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue remains very small and has not grown meaningfully over the past several years, suggesting the business is still early in commercial adoption. Gross profit has hovered around break-even to slightly negative, reflecting high production and service costs relative to sales. Operating and net losses have been consistent and sizeable each year, indicating the company has not yet reached an efficient scale. Losses per share have been gradually improving but remain clearly negative, so profitability still appears a multi‑year challenge that depends on stronger product uptake and operating leverage.

Balance Sheet

Balance Sheet The balance sheet shows a relatively modest asset base that has shrunk from its peak after going public, reflecting cash burn and limited new investment. Cash levels are now much lower than they were shortly after the IPO, which heightens the importance of either improving cash generation or accessing additional capital in the future. Debt is low, which reduces financial strain from interest payments, and equity still makes up most of the capital structure, but accumulated losses are steadily eroding that equity cushion. Overall, the company is not over-levered, but its financial flexibility is tied closely to managing cash and funding needs carefully.

Cash Flow

Cash Flow The business has been consistently using cash rather than generating it. Operating cash flow has been negative for several years, broadly matching the pattern of operating losses. Free cash flow is also negative but has shown slight improvement as capital spending has remained modest. This means the company is funding its operations primarily through the cash it raised previously and, potentially, future financing. The key risk is that if revenue does not scale and margins do not improve, the company may eventually need to raise more capital or cut back on growth investments to sustain operations.

Competitive Edge

Competitive Edge Rapid Micro Biosystems operates in a specialized niche of automated microbial quality control, where it benefits from being an early mover with a focused flagship platform. Its technology automates a slow, manual, and heavily regulated process, which can create strong loyalty and high switching costs once customers integrate the system into their validated workflows. The company holds patents, has domain expertise, and can generate recurring revenue from consumables and service contracts, all of which support a defensible position. However, it competes against larger, well‑funded players in life sciences tools, and its small scale and limited commercial footprint make customer adoption, global sales reach, and service capabilities critical execution risks.

Innovation and R&D

Innovation and R&D Innovation is a clear strength: the Growth Direct platform automates traditional growth-based microbial testing, offering faster results while staying aligned with established regulatory methods. The company is expanding its applications, such as rapid sterility testing, which targets a very important and time-consuming step in drug release. It is also exploring new areas like cell and gene therapy and enhancing software, analytics, and remote monitoring, which can deepen customer stickiness. The collaboration with Merck KGaA’s life science business should broaden distribution and may support joint development, but the commercial impact will depend on how quickly customers adopt these newer applications and how effectively the partnership is executed.

Summary

Rapid Micro Biosystems combines an attractive, automation-focused technology story with a still‑immature financial profile. On the positive side, it operates in a highly regulated, high‑value niche where time savings and data integrity matter greatly, it has a defensible product platform with recurring revenue potential, and it is actively innovating with new applications and partnerships. On the risk side, revenue remains small and flat, losses and cash burn are ongoing, and the balance sheet is far less cash‑rich than shortly after the IPO, which raises future funding and dilution considerations. The company’s long‑term outcome largely hinges on its ability to convert technological advantages and partnerships into broader market adoption, scale its installed base, and move its economic model toward sustainable profitability before financial resources become too tight.

NEWS

November 7, 2025 · 6:00 AM UTC

Rapid Micro Biosystems Reports Third Quarter 2025 Financial Results; Announces Record Multi-System Customer Order and Raises Full-Year Revenue and System Placement Guidance

Read more

October 30, 2025 · 4:45 PM UTC

Rapid Micro Biosystems to Participate in the Stifel 2025 Healthcare Conference

Read more

October 28, 2025 · 5:05 PM UTC

Rapid Micro Biosystems to Announce Third Quarter 2025 Financial Results on November 7, 2025

Read more

September 22, 2025 · 8:00 AM UTC

Trinity Capital Inc. Provides $45 Million in Growth Capital to Rapid Micro Biosystems, Modernizing Healthcare Industry Practices

Read more

September 2, 2025 · 4:45 PM UTC

Rapid Micro Biosystems to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Read more